| Literature DB >> 29402286 |
Prabjit Barn1,2, Luisa Giles3,4, Marie-Eve Héroux5, Tom Kosatsky3,6.
Abstract
BACKGROUND: Acute high level carbon monoxide (CO) exposure can cause immediate cardio-respiratory arrest in anyone, but the effects of lower level exposures in susceptible persons are less well known. The percentage of CO-bound hemoglobin in blood (carboxyhemoglobin; COHb) is a marker of exposure and potential health outcomes. Indoor air quality guidelines developed by the World Health Organization and Health Canada, among others, are set so that CO exposure does not lead to COHb levels above 2.0%, a target based on experimental evidence on toxicodynamic relationships between COHb and cardiac performance among persons with cardiovascular disease (CVD). The guidelines do not consider the role of pathophysiological influences on toxicokinetic relationships. Physiological deficits that contribute to increased CO uptake, decreased CO elimination, and increased COHb formation can alter relationships between CO exposures and resulting COHb levels, and consequently, the severity of outcomes. Following three fatalities attributed to CO in a long-term care facility (LTCF), we queried whether pathologies other than CVD could alter CO-COHb relationships. Our primary objective was to inform susceptibility-specific modeling that accounts for physiological deficits that may alter CO-COHb relationships, ultimately to better inform CO management in LTCFs.Entities:
Keywords: Anemia; Carbon monoxide; Carboxyhemoglobin; Cardiovascular disease; Chronic obstructive pulmonary disease; Indoor air guidelines; Susceptible persons
Mesh:
Substances:
Year: 2018 PMID: 29402286 PMCID: PMC5800074 DOI: 10.1186/s12940-018-0357-2
Source DB: PubMed Journal: Environ Health ISSN: 1476-069X Impact factor: 5.984
Fig. 1Summary of review process
Summary of carbon monoxide (CO) exposure levels and durations and corresponding carboxyhemoglobin (COHb) levels, by health status
| Exposure period | Exposure level (ppm) | Number of subjects | Meana COHb (%) among controls or during control periodb | Meana COHb (%) among exposed persons or after exposure | Mean increase in COHb with exposurec (%) |
|---|---|---|---|---|---|
| Healthy subjects | |||||
| 1 min (5 exposures separated by 7 min each) [ | 7500 | 11 | NR | NR | 2.05 |
| 3–6.65 min [ | 6683 ppm | 15 | 2.08 (SD: 0.08) | NR | – |
| 2.5–3.5 min [ | 5000d | 10 | NR | 3.95 (SD: 1.87) | – |
| 5 min (× 5 exposures separated by 3 min each) [ | 1500 | 11 | NR | NR | 2.08 |
| 3–8 min [ | 3000d | 12 | NR | 6.2 (SD: 0.3) | – |
| 10–30 min [ | 4000 | 12 | NR | 10 | – |
| 30 min [ | 500d | 15 | 1.2 (SD: 0.5) | 8.5 (SD: 0.9) | 7.3 |
| 30–45 min [ | 1200 | 10 | – | 10 | – |
| 1 h | 100 [31]d | 10 | 1.67 (SD: 0.33) | 3.95 (SD: 0.49) | 2.28 |
| 500 [49]d | 15 | 1.2 (SD: 0.5) | 9.4 (SD: 0.6) | 8.2 | |
| 500 [48] | 13 | 1.2 (95% CI: 1.0, 1.4) | 7.0 (95% CI: 6.5, 7.7) | 5.8 | |
| 4 h [ | 35.7 | 30 | 1.5 (SD: 0.27) | 3.03 (SD: 0.71) | 1.53 |
| 74.1 | 30 | 1.3 (SD: 0.39) | 5.1 (SD: 0.57) | 3.80 | |
| 10 days [ | 15d | 15 | 0.5 | 2.4 | 1.90 |
| 50d | 15 | 0.5 | 7.2 | 6.70 | |
| Susceptible groups | |||||
| Subjects with cardiovascular disease | |||||
| 3–120 s [ | 50,000 | 25 | 0.98 | 8.96 | 7.98 |
| 50–70 min [ | 117 (SD: 4.4)d | 63 | 0.6 (SD: 0.02) | 2.0 (SD: 0.05) | 1.4 |
| 253 (SD: 6.1)d | 63 | 0.6 (SD: 0.02) | 3.9 (SD: 0.08) | 3.3 | |
| 1 h | 50 [58] d | 15 | 1.09 (SD: 0.15) | 2.02 (SD: 0.16) | 0.93 |
| 100 [63]d | 24 | 1.5 | 3 | 1.5 | |
| 100 [65]d | 41c | 1.82 (SD: 0.06) | 3.93 (SD: 0.07) | 2.11 | |
| 100 [59]d | 30c | 1.7 | 4.1 | 2.4 | |
| 159 (SD: 25) [68]d | 33c | 0.7 | 3.2 | 2.5 | |
| 200 [64]d | 41 | 1.82 (SD: 0.06) | 5.91 (SD: 0.07) | 4.09 | |
| 292 (SD: 31) [68]d | 33c | 0.7 | 5.1 | 4.4 | |
| 1.5 h | 53 (SD: 6) [53]d | 10 | 1.12 (SD: 1.20) | 5.08 (SD: 1.19) | 3.96 |
| 100 [69]d | 17 | 0.2–2.1 | 4.2 (SD: 0.3) | – | |
| 2 h | 50 [55]d | 10c | 1.03 (0.27) | 2.68 (SD: 0.15) | 1.65 |
| 50 [56]d | 10 | 1.08 | 2.77 | 1.69 | |
| 100 [69]d | 17 | 0.64 | 3.91 | 3.27 | |
| 142 ppm [ | 21 | 0.80 (SD: 0.20) | 17.06 (SD: 1.38) | ||
| 4 h [ | 50d | 10 | 1.3 | 2.9 (range: 1.3–3.8) | 1.6 |
| 100d | 10 | 1.3 | 4.5 (range: 2.8–5.4) | 3.2 | |
| Subjects with chronic obstructive pulmonary disease | |||||
| 1 h [ | 100 | 10 | 1.48 | 4.08 | 2.60 |
| Subjects with anaemia | |||||
| 1 h [ | 50d | 10 | 2.14 (SD: 0.55) | 3.38 (SD: 0.83) | 1.24 |
| Subjects of older age (> 60 years) | |||||
| 3 h [ | 50 | 36 | 1.30 | 2.77 | 1.47 |
aAdditional summary statistics provided where reported, including standard deviation (SD), range, and 95% confidence intervals (CI). COHb levels reported to the number of decimal points reported in the original paper
bRepresents COHb levels after exposure to fresh/filtered air, or pre-CO exposure; NR = not reported
cCalculated as difference between pre (baseline) and post exposure COHb levels where values were reported. Dashed line (−-) indicates that not enough information was available for calculation. The number of decimal points are presented to match values reported in the original paper
dExperimental conditions included exercise
Summary of lowest levels of carboxyhemoglobin (COHb) for which health outcomes have been described, by health status
| Health outcome | Lowest mean COHb for measured responsea (%) | Associated CO exposure | Response |
|---|---|---|---|
| Healthy subjects | |||
| Exercise-induced arrhythmias [ | 5 [ | 1000–3000 ppm for 4–6 min | No effect. |
| Exercise duration [ | 3.95 (SD: 0.49) [ | 100 ppm for 1 h | Decrease in mean exercise duration from 698 to 663 s ( |
| Cardiovascular effects (cardiac output, heart rate, artery diameter, electrocardiogram changes) [ | 2.4 [ | 15 ppm for 10 days (continuous exposure) | Electrocardiogram changes, specifically to |
| Respiratory effects [ | 3.95 (SD: 1.87) [ | 5000 ppm for 2.5–3.5 min | Decrease in mean (sd) inspiratory capacity from 3655 (415) ml to 3380 (419) ml ( |
| Cognitive function [ | 5.1 (SD: 0.57) [ | 74.1 ppm for 4 h | Decreases in performance of visual tracking exercises among high exposure group, compared with low exposure and control groups ( |
| Cytokine production [ | 7 (95% CI: 6.5,7.7) [ | 500 ppm for 1 h | No effect. |
| Visual function [ | 17.06 (SD: 1.38) [ | 11,569 ppm for 4–5 min, followed by 141 ppm for 2 h | No effect. |
| Susceptible groups | |||
| Subjects with cardiovascular disease | |||
| Exercise-induced angina [ | 2.0 (SD: 0.05) [ | 117 ppm for 50–70 min | Decrease in mean (sd) time to onset of angina from 501 (25) seconds to 482 (22) seconds ( |
| Exercise-induced arrhythmias [ | 5.91 (SD: 0.07) [ | 200 ppm for 1 h | Higher frequency of single premature ventricular contractions per hour during exercise among subjects ( |
| Other cardiovascular effects [ | 2.0 (SD: 0.05) [ | 117 ppm for 50–70 min | Decrease in mean (sd) length of time to a threshold ischemic ST-segment change from 576 (27) seconds to 510 (26) seconds ( |
| Cognitive function [ | 3.90 [ | 100 ppm, duration not reported | Decrease in mean performance of visualization test ( |
| Exercise-induced claudication (impairment, pain discomfort in legs) [ | 2.77 [ | 50 ppm for 2 h | Decrease in mean (sd) exercise time until onset of intermittent claudication from 174 (49) to 144 (38) seconds. |
| Subjects with chronic obstructive pulmonary disease | |||
| Exercise performance [ | 4.08 [ | 100 ppm for 1 h | Decrease in mean (sd) exercise duration from 219 (48) to 147 (28) seconds ( |
| Subjects with anemia | |||
| Exercise performance [ | 3.38 (SD: 0.83) [ | 50 ppm for 1 h | Decrease in mean (sd) exercise duration from 221 (72) to 217 (73) seconds ( |
| Subjects of older age (> 60 years) | |||
| Cognitive function [ | 5.0 [ | 200 ppm for 1 h and 50 ppm for 2 h | No effect. |
aAdditional summary statistics provided where reported, including standard deviation (SD), range, and 95% confidence intervals (CI)